Inclusion is Our Goal
Is your cancer included in the STARTRK-2 study?
We are dedicated to removing all barriers for potential participants to access this investigational medicine.
Entrectinib is designed to have a potent effect on tumors with a major genetic alteration affecting the NTRK (NTRK1, NTRK2, NTRK3), ALK, and ROS1 genes.
> Click on a Disease State below to learn more.
Don't see your diagnosis below?
Ignyta's researchers are working to identify potential additional types of cancer caused by these gene rearrangements.
See if you or a loved one may be eligible for the study.